Vitamin C and Tyrosine Kinase Inhibitor in Lung Cancer Patients With Epidermal Growth Factor Receptor Mutations

  • End date
    Dec 31, 2022
  • participants needed
  • sponsor
    Clifford Hospital, Guangzhou, China
Updated on 22 January 2021


This trial was to explore whether intravenous vitamin C can prolong resistance time of Tyrosine Kinase Inhibitor(TKI) on lung adenocarcinoma patients with Epidermal Growth Factor Receptor(EGFR) mutations, and can benefit NSCLC patients.


The effects of vitamin C in combination with tyrosine kinase inhibitor on tumor size, tumor markers, inflammatory factor levels, quality of life, duration of resistance, progression-free survival, and overall survival time were evaluated.

This trial is a low risk treatment, and has developed the appropriate safety measures and contingency plans to ensure patients' safety in the whole process.

Patients will be followed up after the end of the trial, and follow-up observations will be performed every month during the first year. Followed every 3 months in the second year for 3 years.

Condition Non-Small Cell Lung Cancer
Treatment Vitamin C, Tyrosine Kinase Inhibitor
Clinical Study IdentifierNCT03799094
SponsorClifford Hospital, Guangzhou, China
Last Modified on22 January 2021


Yes No Not Sure

Inclusion Criteria

Primary non-small cell lung cancer (adenocarcinoma) with EGFR mutations on exons 19 and 21
years old to 75 years old
During the trial, patients were prescribed TKI drugs(received initial treatment within 2 months, or change medication within 2 months) and did not receive chemotherapy or radiotherapy at the same time
Eastern Cooperative Oncology Group (ECOG) performance status are 0 to 2
Expected survival over 3 months
Household registration is Guangdong Province

Exclusion Criteria

Co-morbid conditions that affect survival: end stage congestive heart failure, unstable angina, myocardial infarction (within the past 6 weeks), and uncontrolled blood sugars of greater than 300 mg/dL, known chronic active hepatitis or cirrhosis
Glucose-6-phosphate dehydrogenase deficiency (G6PD) (a relative contraindication)
Patients who are allergic to vitamin C
Patients with HIV and other infectious diseases
Patients who are taking anticoagulants and have coagulopathy
Combine dysfunction of important organs such as heart, lung, liver and kidney
Patients with impaired renal function (serum creatinine content > 1.2 mg/dL)
Compromised liver function with evidence of Serum total bilirubin content, Serum alanine aminotransferase(ALT) and aspartate transaminase(AST)> 2 times normal reference value
Pregnant or lactating female
Smoking and alcohol abuse patients
Anti-infective treatment is required for systemic or localized serious infections
Patients with hyperuricacidemia (normal: 91-456 mol / 24h (8-40mg / 24h))
Wilson's disease
Evidence of significant psychiatric disorder by history or examination that would prevent completion of the study or preclude informed consent
Any condition that impairs the patients' ability to swallow, which impairs drug absorption or drug kinetic parameters, including any kind of gastrointestinal resection or surgery
History of surgery of visceral organs within 6 weeks before the study
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note